Clinical Trials · NCT07527195
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 100
- Start date
- Apr 2026
- Locations
- 1 site, Denmark
- Primary endpoint
- Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle